PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Vonoprazan

Drugs in development · updated 30 October 2026

Vonoprazan: clinical trials and development status

Other names and codes: Voquezna

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Vonoprazan is in 11 active clinical trials (recruiting or ongoing, phases I–III) for 8 diseases. The most advanced phase is III.

11Active trials
IIIMost advanced phase
8Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Vonoprazan and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Gastroesophageal reflux diseaseIII1NCT07752407
UlcerIII1NCT07608536
Delayed graft functionI–II1NCT07275632
Eosinophilic esophagitisII1NCT06851559
Esophageal and gastric varicesII1NCT07267260
FibrosisII1NCT07267260
Helicobacter infectionII1NCT07293910
Portal hypertensionII1NCT07267260

Everything on Vonoprazan

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch